Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Disease area: Airway diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Calancea (Chisinau, Republic of Moldova), N. Ghicavii (Chisinau, Republic of Moldova), A. Cretu (Chisinau, Republic of Moldova), N. Antonova (Chisinau, Republic of Moldova), S. Oprea (Chisinau, Republic of Moldova), S. Matcovschi (Chisinau, Republic of Moldova). Evaluation in administration of angiotensin II receptor antagonist Valsartan in the treatment of hypertension patients with chronic obstructive pulmonary disease.. 2468

Member's Comments

No comment yet.

Related content which might interest you: Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Source: Eur Respir J 2006; 27: 972-979 Year: 2006 Effect of angiotensin II receptor antagonists on cardiovascular disorders in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension Source: Eur Respir J 2015; 46: 283-286 Year: 2015 Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018 C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Effect of phosphodiesterase 5 inhibitor in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019